通过临床药物和胆固醇对人类GlyT1的调节
Na Li1, Yiqing Wei2,3, Renjie Li2,3
1Heart Center and Beijing Key Laboratory of Hypertension, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Nature communications
|March 12, 2025
概括
这项研究揭示了甘氨酸载体1 (GlyT1) 功能和抑制的结构基础. 胆固醇结合对GlyT1构造变化至关重要,影响谷氨酸信号传递和潜在的精神分裂症治疗.
科学领域:
- 神经科学是一个神经科学.
- 结构生物学 结构生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 甘氨酸载体1 (GlyT1) 调节细胞外甘氨酸水平,影响谷氨酸作用的神经传递.
- 抑制GlyT1是一种通过增强NMDA受体功能来治疗精神分裂症认知缺陷的治疗策略.
- 药物和脂质对GlyT1调节的机制尚未完全理解.
研究的目的:
- 确定GlyT1功能和抑制的结构机制.
- 阐明GlyT1与抑制剂和胆固醇的结合相互作用.
- 了解胆固醇在GlyT1形态动态中的作用.
主要方法:
- 低温电子显微镜 (cryo-EM) 用于确定GlyT1结构.
- 生物化学试验用于研究运输动力学.
- 对Apo-GlyT1和GlyT1抑制剂复合物的结构分析.
主要成果:
- 阿波-GlyT1的三个不同的构造显示了其运输周期平衡.
- 用伊克莱珀丁和萨尔科辛结合GlyT1的结构显示出独特的抑制剂结合姿势.
- 确定了三个胆固醇结合位点,其中两个依赖于形状.
- 胆固醇结合平衡对于GlyT1形态转变至关重要.
结论:
- 提供了关于GlyT1结构和构造状态的原子层次见解.
- 溶解剂药物和脂质相互作用与GlyT1.1.
- 强调胆固醇在GlyT1调节和功能中的重要作用.
- 进步对GlyT1的理解,用于神经系统疾病的潜在治疗发展.
相关概念视频
Glucose Absorption Into the Small Intestine
31.1K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.1K
Cholesterol: Significance and Regulation
492
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
492
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
501
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
501
Hormones Regulating Blood Glucose
3.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.0K
Glucagon-like Receptor Agonists
289
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
289
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
141
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
141


